Complete Remission of Hepatocellular Carcinoma With Atezolizumab and Bevacizumab Following Prior B-cell Depletion.

J Immunother · 2026 · PMC12662147 · PMID 41114633

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

After initiation of atezolizumab and bevacizumab, we had discovered a decreasing trend of CD8+ T cells on our patient.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.